Verify any claim · lenz.io
Claim analyzed
Health“Individuals with MTHFR gene mutations have a higher risk of adverse reactions to vaccines compared to individuals without these mutations.”
Submitted by Vicky
The conclusion
The evidence does not support the broad assertion that MTHFR mutations increase adverse reaction risk across vaccines generally. The only direct peer-reviewed finding linking MTHFR to vaccine adverse events comes from a single 2008 smallpox vaccination study — a vaccine no longer in routine use. The most current synthesis, a 2023 systematic review, found data too sparse for firm conclusions and identified only a "possible association." Clinical institutions do not recognize MTHFR status as a contraindication or established risk factor for vaccination.
Based on 11 sources: 2 supporting, 7 refuting, 2 neutral.
Caveats
- The claim overgeneralizes from a single study on a discontinued smallpox vaccine to all vaccines — a hasty generalization not supported by the broader evidence base.
- The 2023 systematic review (the most comprehensive available synthesis) explicitly states the evidence is too sparse for firm conclusions, identifying only a 'possible association' rather than an established risk.
- Major clinical institutions, including Children's Hospital of Philadelphia, do not recognize MTHFR mutations as a contraindication or risk factor for vaccination, and do not recommend MTHFR testing to guide vaccine decisions.
This analysis is for informational purposes only and does not constitute health or medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional before making health-related decisions.
Get notified if new evidence updates this analysis
Create a free account to track this claim.
Sources
Sources used in the analysis
This systematic review demonstrated a possible association between the MTHFR gene variants and COVID-19 severity, thromboembolic events, and adverse events following vaccination. However, the paucity of robust data precluded any firm conclusions being drawn. Further prospective trials are required to determine the connection between the MTHFR gene variant and COVID-19 infection and vaccination outcomes.
A nonsynonymous SNP in methylenetetrahydrofolate reductase (MTHFR) was associated with AE risk in both trials (odds ratio [OR]; 95% confidence interval [CI]); p-value [p]): (OR=2.3; CI=1.1–5.2; p=0.04) and (OR=4.1; CI=1.4–11.4; p<0.01). Genetic polymorphisms in an enzyme previously associated with adverse reactions to a variety of pharmacologic agents (MTHFR) and an immunological transcription factor (IRF1) were associated with AEs after smallpox vaccination in two independent study samples.
The investigators found specific SNPs/haplotypes in the MTHFR (enzyme 5,10-methylenetetrahydrofolate reductase, non-synonymous rs1801133, p<0.01) and IRF1 (interferon regulatory factor-1, rs9282763 and synonymous rs839, p=0.03) genes that were significantly associated with AEs in both studies [44]. Genetic variants in the MTHFR gene have been previously associated with adverse reactions to other pharmacologic biologics [45,46].
There is insufficient evidence linking MTHFR mutations to adverse vaccine reactions, and healthcare experts do not support MTHFR testing as a predictor of vaccine response or justification for vaccine exemptions. Experts generally agree that vaccination remains safe and necessary despite concerns related to MTHFR genetics.
People with the MTHFR mutation can be vaccinated since the mutation has not been found to be problematic when it comes to vaccinations. Likewise, vaccine ingredients have been studied and are safe in the quantities presented in vaccinations.
The only published evidence linking MTHFR to vaccine reactions comes from a 2008 study examining smallpox vaccination. We do NOT have strong clinical evidence linking MTHFR variants to vaccine injury or outcomes.
No scientific evidence supports the claim that mutations in the MTHFR gene are associated with either birthmarks or a higher risk of adverse reactions to vaccines. This claim is likely based on a single study published in 2008 in the Journal of Infectious Diseases exploring whether one mutation in the MTHFR gene increased the risk of adverse effects to an experimental vaccine against smallpox.
No scientific evidence pointing to the common MTHFR variants playing a role in vaccination adverse events. Researching the studies on MTHFR variants and vaccination injuries or adverse events lead me to exactly one study. Seriously. One study — on a vaccine that is no longer given.
There is no known contraindication to receiving the COVID-19 vaccine if you have the MTHFR gene mutation. In fact, some studies suggest that certain variations of this mutation may increase vulnerability to COVID-19 infection.
MTHFR mutations do not directly affect vaccine response. Vaccination recommendations are generally based on public health guidelines, and individuals should follow their healthcare provider's advice.
There has been a small study on MTHFR variants and vaccination adverse events that could lead to injuries. In the study, they found that individuals with an MTHFR C677T variant had an increased possibility of an adverse event. Since the Smallpox vaccine has not been used in the United States general public in about 45 years, this does not relate to other vaccines many are concerned about.
What do you think of the claim?
Your challenge will appear immediately.
Challenge submitted!
Expert review
How each expert evaluated the evidence and arguments
Expert 1 — The Logic Examiner
The logical chain from evidence to claim is critically weak: Source 2 provides direct empirical support (ORs of 2.3 and 4.1) but is confined to a single, discontinued smallpox vaccine in 2008, making any generalization to "vaccines" broadly a hasty generalization; Source 1's 2023 systematic review explicitly withholds firm conclusions due to sparse data, meaning it cannot logically anchor the sweeping claim; and Sources 4, 5, 7, 8, and 10 — including CHOP and Science Feedback — consistently affirm that no generalizable evidence supports elevated adverse-reaction risk across vaccines for MTHFR carriers. The claim as stated ("higher risk of adverse reactions to vaccines") is an overgeneralization: the only peer-reviewed empirical signal is vaccine-specific and context-limited, the best available synthesis refuses to draw firm conclusions, and the proponent's rebuttal correctly identifies authority gaps in opposing sources but cannot overcome the fundamental scope mismatch between a single-vaccine finding and a universal claim about vaccine reactions — making the claim Misleading rather than True or False outright.
Expert 2 — The Context Analyst
The claim presents a broad, generalized assertion that individuals with MTHFR mutations have a "higher risk of adverse reactions to vaccines" — but the supporting evidence is critically narrow: it derives almost entirely from a single 2008 study on smallpox vaccination (Source 2), a vaccine no longer in general use, and a 2023 systematic review (Source 1) that explicitly states the data are too sparse for firm conclusions and calls for further prospective trials. The claim omits that (a) the association has only been demonstrated for one discontinued vaccine, (b) the scientific consensus from clinical institutions like CHOP (Source 5) and fact-checkers like Science Feedback (Source 7) is that no generalizable evidence supports this link, (c) healthcare experts do not recommend MTHFR testing as a predictor of vaccine response (Source 4), and (d) the 2023 systematic review's "possible association" language signals an open scientific question, not an established elevated risk. Once the full picture is considered — that the claim overgeneralizes from a single outdated, niche finding to all vaccines, while the broader scientific and clinical consensus finds insufficient evidence to support the generalized claim — the claim as stated creates a misleading impression of established, broad risk that the evidence does not support.
Expert 3 — The Source Auditor
The highest-authority sources in this pool are Source 1 (PubMed systematic review, 2023) and Source 2 (PMC-NIH, 2008), both peer-reviewed and highly credible. Source 1 — the most current and broadest synthesis — explicitly states that "paucity of robust data precluded any firm conclusions," identifying only a "possible association" with post-vaccination adverse events. Source 2 does provide statistically significant odds ratios from two independent smallpox vaccination trials, and Source 3 (PMC, also high-authority) corroborates MTHFR's association with adverse reactions to pharmacologic agents broadly. However, the smallpox vaccine is no longer in general use, and no high-authority source generalizes this finding to vaccines broadly. The refuting sources (Sources 5, 7, 8) are lower-authority clinical education pages, blogs, or science-communication outlets — not peer-reviewed research — and while their consensus is directionally consistent, they do not carry the evidentiary weight of Sources 1–3. The net picture from the most reliable sources is: there is a plausible, peer-reviewed signal (Source 2, Source 3) but it is narrow in scope (one discontinued vaccine), and the only broad synthesis (Source 1) stops well short of confirming the sweeping claim as stated. The claim as worded — that MTHFR mutation carriers have a "higher risk of adverse reactions to vaccines" generally — overstates what the best evidence supports, making it misleading rather than clearly true or false.
Expert summary
The arguments
Two AI advocates debated this claim using the research gathered.
Argument for
Peer-reviewed research from highly authoritative sources directly supports the claim: Source 2 (PMC - NIH) found that a nonsynonymous SNP in MTHFR was associated with adverse event risk in two independent smallpox vaccination trials with odds ratios of 2.3 and 4.1, while Source 3 (PMC) corroborates this by confirming that MTHFR genetic variants have been "previously associated with adverse reactions to other pharmacologic biologics," establishing a broader pattern beyond a single vaccine. Furthermore, Source 1 (PubMed), a 2023 systematic review, explicitly identifies "a possible association between the MTHFR gene variants" and "adverse events following vaccination," and while it calls for further study, it does not refute the association — meaning the totality of peer-reviewed evidence consistently points toward elevated risk, not away from it.
You're trying to generalize from a single, niche context: Source 2's association is limited to smallpox vaccination trials, and Source 1 (the only broad synthesis) explicitly says the data are too sparse for firm conclusions—so you can't validly leap from “possible association” to the motion's sweeping claim of higher vaccine-reaction risk in general. And your appeal to Source 3's “other pharmacologic biologics” line is a classic scope shift: it's not evidence about vaccines broadly, and it doesn't overcome the central problem that robust, vaccine-wide evidence is lacking per Source 1.
Argument against
The best available synthesis finds only a “possible association” between MTHFR variants and post-vaccination adverse events but explicitly concludes that the evidence base is too sparse for firm conclusions (Source 1, PubMed systematic review), which is incompatible with the broad claim that MTHFR mutations generally confer higher vaccine-reaction risk. The lone supportive signal comes from a 2008 smallpox-vaccine study (Source 2, PMC-NIH; echoed conceptually in Source 3, PMC), while multiple independent reviews and clinical-education sources stress that this single, outdated context does not generalize and that no solid evidence shows MTHFR mutations are problematic for vaccination overall (Sources 5, CHOP; 7, Science Feedback; 8, Genetic Lifehacks; 11, Living with MTHFR).
Your argument commits a classic appeal to quantity fallacy — you stack Sources 5, 7, 8, and 11 against the claim, yet none of these are peer-reviewed studies; they are clinical education pages and blogs with notably lower authority scores than Sources 1, 2, and 3, meaning their consensus-by-volume cannot outweigh the empirical weight of two independent randomized trial findings (Source 2) and a 2023 systematic review that explicitly identifies a "possible association" with post-vaccination adverse events (Source 1). You also mischaracterize Source 1's conclusion as a refutation — it is not; a systematic review calling for "further prospective trials" while acknowledging a possible association is precisely how science signals an emerging, not disproven, relationship, and combined with Source 3's confirmation that MTHFR variants are "previously associated with adverse reactions to other pharmacologic biologics," the evidence trajectory supports elevated risk, not the absence of it.